ABSTRACT
@#AIM: To investigate the correlation between elipsode zone(EZ)integrity and best corrected visual acuity(BCVA)of eyes with diabetic macular edema(DME), and to determine the prognostic factors of visual acuity. <p>METHODS: We studied 62 eyes of 39 patients with DME. Using spectral domain optical coherence tomography(SD-OCT), disrupted elipsode zone length were measured, and the eyes were categorized into three groups according to elipsode zone: 1)Group A: with a completely visible elipsode zone; 2)Group B: with a disrupted elipsode zone and the length of disruption within 200μm;(3)Group C: with a disrupted elipsode zone and the length of disruption longer than 200μm. We also evaluated the presence or absence of hard exudates(HE), serous retinal detachment(SRD), central macular thickness(CMT)using SD-OCT. Pearson analysis testing was performed over the BCVA and the elipsode zone integrity, CMT, existence of SRD and HE, age, sex, duration of diabetes, HbA1c, duration of DME, stage of diabetic retinopathy, and DME type. <p>RESULTS: Before treatment, BCVA(LogMAR)in the Group A(0.44±0.18)or Group B(0.64±0.16)was significantly better than that in the Group C(0.74±0.21)(<i>P</i><0.001). CMT had no difference between Group A(403.40±90.32μm), Group B(408.44±95.98μm)or Group C(421.29± 98.32μm, <i>P</i>=0.805). Analysis showed that elipsode zone integrity had close correlation coefficient with BCVA(<i>r</i>=-0.673, <i>P</i><0.001), CMT had weak correlation with BCVA(<i>r</i>=-0.344, <i>P</i><0.001). Other factors SRD, HE and duration of DME did not correlate with BCVA. <p>CONCLUSION: The integrity of elipsode zone are closely associated with BCVA in DME. CMT are weakly associated with BCVA in DME.
ABSTRACT
AIM: To evaluate the efficacy of intravitreal Conbercept combined with retinal photocoagulation in treating diabetic retinopathy (DR) with diabetic macular edema (DME). METHODS: Prospective case study. Totally 48 patients (80 eyes) diagnosed as DR with DME randomized to combined group and laser group. Among them, there were 4 patients with 5 eyes in the moderate stage of non-proliferative DR (NPDR), 38 patients with 65 eyes in the severe stage of NPDR, and 6 cases with 10 eyes in the stage of proliferative DR (PDR). Intravitreal conbercept (IVC) and pan retinal photocoagulation (PRP) were performed in the combined group; the macular grid pattern laser photocoagulation and PRP were performed in the laser group. Best corrected visual acuity (BCVA), central macular thickness (CMT) and laser energy were tested at baseline and repeated at 1wk,1,3,6,and 12mo after PRP. RESULTS: Repeated measures showed an effect of treatment in combined group. Combined group induced increased BCVA at 1wk, 1 and 3mo after PRP, and remained stable in 6 and 12mo after PRP. Laser group induced increased BCVA at 1 and 3mo after PRP, and remained stable in 1wk,6 and 12mo after PRP. Combined group induced decreased CMT at 1wk, 1 and 3mo post PRP,and remained stable in 6 and 12mo after PRP. Laser group induced decreased CMT at 1 and 3mo after PRP, and remained stable in 1wk,6 and 12mo post PRP. There was no laser spot fusion was observed in the two groups during the follow- up. Laser energy in the combined group was lower than that in the laser group. No complications were observed during the follow-up. CONCLUSION: IVC and retinal photocoagulation significantly improves visual and anatomic outcomes in patients with DR complicated with DME. Long - term efficacy remains to be seen.
ABSTRACT
AIM:To investigate the effect and safety of intravitreous injection of conbercept ( 0. 5mg ) on macular edema secondary to central retinal vein occlusion ( CRVO) . ·METHODS: According to the selective criteria, from October 2014 to October 2015, 48 cases ( 48 eyes ) of patients with macular edema secondary to CRVO were collected, which were divided randomly into conbercept group ( 24 cases, 24 eyes ) and control group ( triamcinolone acetonide 4mg/0. 1mL, 24 cases , 24 eyes ) . The best-corrected visual acuity ( BCVA ) , intraocular pressure, intravitreous injection, fundus oculi, central macular thickness ( CMT ) and related complications were observed before and 1wk, 1, 3, 6 and 12mo after intravitreous injection. · RESULTS: There was no difference on BCVA, intraocular pressure, intravitreous injection, fundus oculi and CMT between the two groups before operations ( P>0.05). There were no significant differences (P>0.05) of the BCVA between two groups after treatment for 1wk, 1, 3, 6 and 12mo. Before and after treatment, the decrease of CMT in conbercept group was respectively 130. 17 ± 1. 72μm, 253. 33 ±3. 14μm, 318. 00±1. 41μm, 20. 01±1. 21μm and 15. 09 ± 1. 41μm, and no related complications. The decrease of CMT in control group was respectively 132. 5± 2.07μm, 249.67±1.21μm, 317.50±4.23μm, 18.01±1.41μm and 16. 09 ± 1. 31μm, and no related complications. There were no significant differences (F=6. 882, P=0. 663>0. 05) of CMT between two groups after treatment for 1wk, 1, 3, 6 and 12mo. Injection times were respectively 2. 83 ± 0. 72 and 3. 17 ± 0. 71 in control group and conbercept group, and the difference between two groups has no statistical significance (P>0. 05). There were 4 cases (17%) of paracentesis of anterior chamber, 3 cases ( 13%) of intraocular hypertension and 1 case ( 4%) of complicated cataract in control group. There was no related complications in conbercept group. ·CONCLUSION: Intravitreous injection of conbercept for macular edema secondary to CRVO is effective, safe and less complications.
ABSTRACT
<p><b>OBJECTIVE</b>To observe the therapeutic effect of vascular endothelial growth factors 165 (VEGF165) gene expressing mesenchymal stem cells (MSCs) in chronic myocardial infarction model by providing enhanced cardioprotection, followed by angiogenic effects in infarcted myocardium.</p><p><b>METHODS</b>Recombinant adenovirus vector carrying VEGF165 gene (rAd-VFGF165) was constructed. MSCs were harvested through gradient centrifugation, then were cultivated, multiplied and expanded. Recombinant adenoviruses mediated VEGF165 gene were transfected into MSCs, and the MSCs were labelled by DAPI. The left anterior descending branch of rabbits were ligated to establish a myocardial infarction model; and the animals survived for 6 weeks were randomly divided into three groups: VEGF165-expressing MSCs transplanted (Group I), MSCs transplanted (Group II) and dulbecco modified eagles medium injected (Group III). At 4 weeks after cell transplantation, the MSCs were detected by DAPI staining in infarcted region. The cardiac functions were estimated by UCG. The microvascular density in infarcted area were estimated through CD34 immunohistochemical analysis.</p><p><b>RESULTS</b>Four weeks after cell transplantation, ejection fraction, E wave/A wave ratio and capillary density of the infarcted region were most improved in Group I compared with Group II and control group (P < 0.05). DAPI positive cells were most increased in Group I.</p><p><b>CONCLUSIONS</b>The transplantation of VEGF165-expressing MSCs had a better therapeutic effect than the transplantation of simplex MSCs. This combined strategy of MSCs transplantation with vgene therapy could be a useful therapy for the treatment of myocardial infarction.</p>
Subject(s)
Animals , Female , Male , Rabbits , Adenoviridae , Genetics , Cells, Cultured , Disease Models, Animal , Genetic Vectors , Mesenchymal Stem Cell Transplantation , Methods , Mesenchymal Stem Cells , Cell Biology , Metabolism , Myocardial Infarction , Pathology , General Surgery , Random Allocation , Transfection , Treatment Outcome , Vascular Endothelial Growth Factor A , Genetics , PhysiologyABSTRACT
Prostate stem cell antigen (PSCA), a homologue of the Ly-6/Thy-1 family of cell surface antigen, is expressed by a majority of human prostate cancers and is a promising target for prostate cancer immunotherapy. To obtain the specific peptide binding with PSCA for targeted immunotherapy, PSCA gene was obtained by RT-PCR from human prostate cancer cell line DU145 and the transcated PSCA (tPSCA) gene was cloned into vector pQE30 for soluble expression in E. coli. The identity of recombinant tPSCA was confirmed through ELISA and western blot by use of anti-PSCA monoclonal antibody. Then the 12-peptide phage display library was screened with the purified tPSCA protein for its specific binding peptide through 3 rounds panning. For identifying the peptide's specificity, the peptide was coupled with EGFP (enhanced green fluorecent protein) by recombinant DNA technology and the recombinant coupled protein was termed 11-EGFP. The binding specificity with tPSCA of 11-EGFP was further confirmed by ELISA and competitive inhibition experiment. Flow cytometry demonstrated its binding specificity with cell line DU145. In conclusion, a 12-amino-acid peptide which could bind with PSCA specifically was found and it may be a potential tool for targeted immunotherapy of prostate carcinoma.